Alto Neuroscience plans to use USD 100 million offering proceeds to expand ALTO-207 Phase 3 program in treatment-resistant depression
ANRO•Proceeds to support ALTO-207 development
Alto Neuroscience plans to use new capital to accelerate and expand clinical development of ALTO-207.
Funds target an additional planned Phase 3 trial of ALTO-207 as monotherapy for treatment-resistant depression.
Proceeds also earmarked for general working capital to support ongoing operations.
